14 citations
,
October 2003 in “Annals of Oncology” In this study, the researchers observed that the severity of capecitabine-induced hand-foot syndrome in advanced gastric cancer patients was not linked to the IVS14+1G→A mutation in the DPYD gene.
The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.
35 citations
,
January 2004 in “European journal of oncology nursing” In patients undergoing treatment with capecitabine for colon cancer and metastatic breast cancer, this study observed that hand-foot syndrome occurred more frequently than with intravenous 5-FU, but other side effects were less common.
December 2025 in “Drug Design Development and Therapy” This retrospective study reported that in HER-2-negative metastatic breast cancer patients, anlotinib combined with taxane/capecitabine showed superior disease control rate, progression-free survival, and overall survival compared to bevacizumab plus chemotherapy, with both treatments having tolerable safety profiles.
7 citations
,
October 2019 in “Klinická onkologie” This review discusses the impact of oncological therapy on hair loss, highlighting that while most alopecia is reversible, it can be permanent depending on treatment type and factors.